Global Uterine Fibroid Diagnostics and Therapeutics Market- Forecast and Analysis (2020-2027): by Type, by Diagnosis, by Treatment, and by Region.

Market Scenario

Global Uterine Fibroid Diagnostics and Therapeutics Market was valued at USD xx Mn in 2019 and is expected to reach USD xx Mn by 2027 at a CAGR of 3.1% over the forecast period 2020-2027.   Global Uterine Fibroid Diagnostics and Therapeutics Market The report covers an in-depth analysis of COVID 19 pandemic impact on Global Uterine Fibroid Diagnostics and Therapeutics Market by region and on the key players’ revenue affected till July 2020 and expected short term and long-term impact on the market. Uterine Fibroid Diagnostics and Therapeutics Market overview Uterine fibroid is a tumor that develops in the muscular wall of the uterus. It arises from the smooth muscle tissues of the uterus. This non-cancerous tumor is also known as, fibroleiomyoma, leiomyoma (benign tumor), myoma, and fibromyoma. They vary from size-to-size from tiny to larger. Fibroids are the common form especially during pregnancy periods of the woman. A fibroid tumor that is uncountable is known as uterine leiomyomatosis. The uterine fibroids, often during 5 months of pregnancy, help the uterus develop. If it is malignant also known as leiomyosarcoma is very uncommon. It causes extreme bleeding swelling of the abdomen, lower back pain, and mental structural cramping. Increasing the cure for these diseases has fuelled the growth of the market. Ultrasound instruments, due to their usefulness and popularity for gynaecological purposes, are commonly used to diagnose uterine fibroids. It also emits no harmful rays that can affect the foetus (if women are pregnant with uterine fibroids), raising its choice among radiologists. Uterine Fibroid Diagnostics and Therapeutics Market Dynamics The growth of this market has been motivated by rise in prevalence due to inheritance and growing number of therapies to cure this disease. Besides, the global Uterine Fibroid Diagnostics and Therapeutics market is expected to grow owing to increasing health care expenditure and increasing fibroids drugs market over the forecast period. The change in lifestyle, changing in food habits, and hectic lifestyle increases the demand for healthcare products and dietary supplements. The demand to cure such diseases has led the manufacturers to take keen interest in Uterine Fibroid Diagnostics and Therapeutics market. However, increasing high costs of these machines with the adoptions of robots in surgeries are expected to restrain the market. Besides, government stringent regulations may hamper the market for the Uterine Fibroid Diagnostics and Therapeutics market. The woman pregnancy and consumer awareness about various diagnosed technique such as, computed tomography (CT) scanners, medical resonance imaging (MRI) scanners and ultrasound devices have boosted the demand for Uterine Fibroid Diagnostics and Therapeutics market. Various physician has adopted these artificial intelligence robotic techniques owing to the positive responses and better results on the uterine fibroid. Global Uterine Fibroid Diagnostics and Therapeutics Market: Market Segmentation Global Uterine Fibroid Diagnostics and Therapeutics Market is Segmented by Type Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others), by Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed Tomography (CT), Ultrasounds and others), by Treatment (Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy), and by Region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). Global Uterine Fibroid Diagnostics and Therapeutics Market: Regional Analysis The regional analysis of the worldwide uterine fibroid diagnostics and therapeutics market is segregated across North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The worldwide demand for Uterine Fibroid Diagnostics and Therapeutics is expected to record the greatest growth in the Asia Pacific region. Increasing number of women of reproductive age (WRA) has positive impact on the Uterine Fibroid Diagnostics and Therapeutics market. Increasing investment and consumer changing lifestyle is expected to increase the demand for fibroid diagnostics market. Besides, approximately 75 million WRAs were registered in 2014, according to the Centers for Disease Control and Prevention (CDC), and this number is projected to increase with the growing number of women worldwide. According to the World Data Book, in 2011 , the total population of women was about 3,439.4 million and this number is projected to increase predominantly in developing countries such as India and China due to improved education systems has positive impact on the Uterine Fibroid Diagnostics and Therapeutics market. Report covers in-depth analysis of key development, marketing strategies, supply-side and demand side indicators and company profiles of market leaders, potential players, and new entrants. Key players operating in this market are adopting various organic and inorganic growth strategies such as merger& acquisitions, joint ventures, collaborations, expansion, new product launches and patents to increase their regional presence and business operations. The objective of the report is to present a comprehensive analysis of the Global Uterine Fibroid Diagnostics and Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Uterine Fibroid Diagnostics and Therapeutics Market dynamics, structure by analyzing the market segments and project Global Uterine Fibroid Diagnostics and Therapeutics Market Clear representation of competitive analysis of key players by price, financial position, Product portfolio, growth strategies, and regional presence in the Global Uterine Fibroid Diagnostics and Therapeutics Market make the report investor’s guide.

Scope of Global Uterine Fibroid Diagnostics and Therapeutics Market

Global Uterine Fibroid Diagnostics and Therapeutics Market Segmentation by Type

• Subserosal Fibroids • Intramural Fibroids • Submucosal Fibroids • Other

Global Uterine Fibroid Diagnostics and Therapeutics Market Segmentation by Diagnosis

• Medical Resonance Imaging (MRI) scanners • Computed Tomography (CT) • Ultrasounds • Others

Global Uterine Fibroid Diagnostics and Therapeutics Market Segmentation by Treatment

• Uterine Fibroid Embolization • Magnetic Resonance Guided Focused Ultrasound • Myolysis • Endometrial Ablation • Hysterectomy • Myomectomy

Global Uterine Fibroid Diagnostics and Therapeutics Market Segmentation by Region

• North America • Europe • Asia-Pacific • South America • Middle East & Africa

Global Uterine Fibroid Diagnostics and Therapeutics Market Major Players

• Roche Ltd • Abbott Laboratories • Becton • Dickinson and Company and Siemens Healthcare • AstraZeneca • Cook Medical Inc. • Boston Scientific Corporation • GE Healthcare • AbbVie Inc. • Hologic

Table of Contents

Global Uterine Fibroid Diagnostics and Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Uterine Fibroid Diagnostics and Therapeutics Market, by Market Value (US$ Bn) and Volume (Ton) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis and Forecast 6.1. Global Uterine Fibroid Diagnostics and Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis and Forecast, by Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type 7.4. Global Uterine Fibroid Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Type 7.5. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Type 7.6. Global Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis, by Type 8. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis and Forecast, by Diagnosis 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis 8.4. Global Uterine Fibroid Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnosis 8.5. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Diagnosis 8.6. Global Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnosis 9. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis and Forecast, by Treatment 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Treatment 9.4. Global Uterine Fibroid Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Treatment 9.5. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Treatment 9.6. Global Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis, by Treatment 10. Global Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Region 10.1. Global Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Region 10.2. Global Uterine Fibroid Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Region 10.3. Global Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis, by Region 11. North America Uterine Fibroid Diagnostics and Therapeutics Market Analysis 11.1. Key Findings 11.2. North America Uterine Fibroid Diagnostics and Therapeutics Market Overview 11.3. North America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type 11.4. North America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 11.4.1. Subserosal Fibroids 11.4.2. Intramural Fibroids 11.4.3. Submucosal Fibroids 11.4.4. Other 11.5. North America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis 11.6. North America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 11.6.1. Medical Resonance Imaging (MRI) scanners 11.6.2. Computed Tomography (CT) 11.6.3. Ultrasounds 11.6.4. Others 11.7. North America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Treatment 11.8. North America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 11.8.1. Uterine Fibroid Embolization 11.8.2. Magnetic Resonance Guided Focused Ultrasound 11.8.3. Myolysis 11.8.4. Endometrial Ablation 11.8.5. Hysterectomy 11.8.6. Myomectomy 11.9. North America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Country 11.10. North America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Country 11.12. U.S. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 11.12.1. Subserosal Fibroids 11.12.2. Intramural Fibroids 11.12.3. Submucosal Fibroids 11.12.4. Other 11.13. U.S. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 11.13.1. Medical Resonance Imaging (MRI) scanners 11.13.2. Computed Tomography (CT) 11.13.3. Ultrasounds 11.13.4. Others 11.14. U.S. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 11.14.1. Uterine Fibroid Embolization 11.14.2. Magnetic Resonance Guided Focused Ultrasound 11.14.3. Myolysis 11.14.4. Endometrial Ablation 11.14.5. Hysterectomy 11.14.6. Myomectomy 11.15. Canada Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 11.15.1. Subserosal Fibroids 11.15.2. Intramural Fibroids 11.15.3. Submucosal Fibroids 11.15.4. Other 11.16. Canada Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 11.16.1. Medical Resonance Imaging (MRI) scanners 11.16.2. Computed Tomography (CT) 11.16.3. Ultrasounds 11.16.4. Others 11.17. Canada Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 11.17.1. Uterine Fibroid Embolization 11.17.2. Magnetic Resonance Guided Focused Ultrasound 11.17.3. Myolysis 11.17.4. Endometrial Ablation 11.17.5. Hysterectomy 11.17.6. Myomectomy 11.18. North America Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis 11.18.1. By Type 11.18.2. By Diagnosis 11.18.3. By Treatment 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Development 12. Europe Uterine Fibroid Diagnostics and Therapeutics Market Analysis 12.1. Key Findings 12.2. Europe Uterine Fibroid Diagnostics and Therapeutics Market Overview 12.3. Europe Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type 12.4. Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 12.4.1. Subserosal Fibroids 12.4.2. Intramural Fibroids 12.4.3. Submucosal Fibroids 12.4.4. Other 12.5. Europe Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis 12.6. Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 12.6.1. Medical Resonance Imaging (MRI) scanners 12.6.2. Computed Tomography (CT) 12.6.3. Ultrasounds 12.6.4. Others 12.7. Europe Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Treatment 12.8. Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 12.8.1. Uterine Fibroid Embolization 12.8.2. Magnetic Resonance Guided Focused Ultrasound 12.8.3. Myolysis 12.8.4. Endometrial Ablation 12.8.5. Hysterectomy 12.8.6. Myomectomy 12.9. Europe Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Country 12.10. Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Norway 12.10.7. Rest of Europe 12.11. Europe Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Country 12.12. Germany Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 12.12.1. Subserosal Fibroids 12.12.2. Intramural Fibroids 12.12.3. Submucosal Fibroids 12.12.4. Other 12.13. Germany Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 12.13.1. Medical Resonance Imaging (MRI) scanners 12.13.2. Computed Tomography (CT) 12.13.3. Ultrasounds 12.13.4. Others 12.14. Germany Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 12.14.1. Uterine Fibroid Embolization 12.14.2. Magnetic Resonance Guided Focused Ultrasound 12.14.3. Myolysis 12.14.4. Endometrial Ablation 12.14.5. Hysterectomy 12.14.6. Myomectomy 12.15. U.K. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 12.15.1. Subserosal Fibroids 12.15.2. Intramural Fibroids 12.15.3. Submucosal Fibroids 12.15.4. Other 12.16. U.K. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 12.16.1. Medical Resonance Imaging (MRI) scanners 12.16.2. Computed Tomography (CT) 12.16.3. Ultrasounds 12.16.4. Others 12.17. U.K. Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 12.17.1. Uterine Fibroid Embolization 12.17.2. Magnetic Resonance Guided Focused Ultrasound 12.17.3. Myolysis 12.17.4. Endometrial Ablation 12.17.5. Hysterectomy 12.17.6. Myomectomy 12.18. France Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 12.18.1. Subserosal Fibroids 12.18.2. Intramural Fibroids 12.18.3. Submucosal Fibroids 12.18.4. Other 12.19. France Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 12.19.1. Medical Resonance Imaging (MRI) scanners 12.19.2. Computed Tomography (CT) 12.19.3. Ultrasounds 12.19.4. Others 12.20. France Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 12.20.1. Uterine Fibroid Embolization 12.20.2. Magnetic Resonance Guided Focused Ultrasound 12.20.3. Myolysis 12.20.4. Endometrial Ablation 12.20.5. Hysterectomy 12.20.6. Myomectomy 12.21. Italy Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 12.21.1. Subserosal Fibroids 12.21.2. Intramural Fibroids 12.21.3. Submucosal Fibroids 12.21.4. Other 12.22. Italy Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 12.22.1. Medical Resonance Imaging (MRI) scanners 12.22.2. Computed Tomography (CT) 12.22.3. Ultrasounds 12.22.4. Others 12.23. Italy Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 12.23.1. Uterine Fibroid Embolization 12.23.2. Magnetic Resonance Guided Focused Ultrasound 12.23.3. Myolysis 12.23.4. Endometrial Ablation 12.23.5. Hysterectomy 12.23.6. Myomectomy 12.24. Spain Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 12.24.1. Subserosal Fibroids 12.24.2. Intramural Fibroids 12.24.3. Submucosal Fibroids 12.24.4. Other 12.25. Spain Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 12.25.1. Medical Resonance Imaging (MRI) scanners 12.25.2. Computed Tomography (CT) 12.25.3. Ultrasounds 12.25.4. Others 12.26. Spain Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 12.26.1. Uterine Fibroid Embolization 12.26.2. Magnetic Resonance Guided Focused Ultrasound 12.26.3. Myolysis 12.26.4. Endometrial Ablation 12.26.5. Hysterectomy 12.26.6. Myomectomy 12.27. Norway Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 12.27.1. Subserosal Fibroids 12.27.2. Intramural Fibroids 12.27.3. Submucosal Fibroids 12.27.4. Other 12.28. Norway Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 12.28.1. Medical Resonance Imaging (MRI) scanners 12.28.2. Computed Tomography (CT) 12.28.3. Ultrasounds 12.28.4. Others 12.29. Norway Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 12.29.1. Uterine Fibroid Embolization 12.29.2. Magnetic Resonance Guided Focused Ultrasound 12.29.3. Myolysis 12.29.4. Endometrial Ablation 12.29.5. Hysterectomy 12.29.6. Myomectomy 12.30. Rest of Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 12.30.1. Subserosal Fibroids 12.30.2. Intramural Fibroids 12.30.3. Submucosal Fibroids 12.30.4. Others 12.31. Rest of Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 12.31.1. Medical Resonance Imaging (MRI) scanners 12.31.2. Computed Tomography (CT) 12.31.3. Ultrasounds 12.31.4. Others 12.32. Rest of Europe Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 12.32.1. Uterine Fibroid Embolization 12.32.2. Magnetic Resonance Guided Focused Ultrasound 12.32.3. Myolysis 12.32.4. Endometrial Ablation 12.32.5. Hysterectomy 12.32.6. Myomectomy 12.33. Europe Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis 12.33.1. By Type 12.33.2. By Diagnosis 12.33.3. By Treatment 12.34. PEST Analysis 12.35. Key Trends 12.36. Key Development 13. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Analysis 13.1. Key Findings 13.2. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Overview 13.3. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type 13.4. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 13.4.1. Subserosal Fibroids 13.4.2. Intramural Fibroids 13.4.3. Submucosal Fibroids 13.4.4. Others 13.5. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis 13.6. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 13.6.1. Medical Resonance Imaging (MRI) scanners 13.6.2. Computed Tomography (CT) 13.6.3. Ultrasounds 13.6.4. Others 13.7. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Treatment 13.8. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 13.8.1. Uterine Fibroid Embolization 13.8.2. Magnetic Resonance Guided Focused Ultrasound 13.8.3. Myolysis 13.8.4. Endometrial Ablation 13.8.5. Hysterectomy 13.8.6. Myomectomy 13.9. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Country 13.10. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. Malaysia 13.10.7. Indonesia 13.10.8. Vietnam 13.10.9. Rest of Asia Pacific 13.11. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Country 13.12. China Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 13.12.1. Subserosal Fibroids 13.12.2. Intramural Fibroids 13.12.3. Submucosal Fibroids 13.12.4. Others 13.13. China Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 13.13.1. Medical Resonance Imaging (MRI) scanners 13.13.2. Computed Tomography (CT) 13.13.3. Ultrasounds 13.13.4. Others 13.14. China Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 13.14.1. Uterine Fibroid Embolization 13.14.2. Magnetic Resonance Guided Focused Ultrasound 13.14.3. Myolysis 13.14.4. Endometrial Ablation 13.14.5. Hysterectomy 13.14.6. Myomectomy 13.15. India Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 13.15.1. Subserosal Fibroids 13.15.2. Intramural Fibroids 13.15.3. Submucosal Fibroids 13.15.4. Others 13.16. India Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 13.16.1. Medical Resonance Imaging (MRI) scanners 13.16.2. Computed Tomography (CT) 13.16.3. Ultrasounds 13.16.4. Others 13.17. India Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 13.17.1. Uterine Fibroid Embolization 13.17.2. Magnetic Resonance Guided Focused Ultrasound 13.17.3. Myolysis 13.17.4. Endometrial Ablation 13.17.5. Hysterectomy 13.17.6. Myomectomy 13.18. Japan Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 13.18.1. Subserosal Fibroids 13.18.2. Intramural Fibroids 13.18.3. Submucosal Fibroids 13.18.4. Others 13.19. Japan Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 13.19.1. Medical Resonance Imaging (MRI) scanners 13.19.2. Computed Tomography (CT) 13.19.3. Ultrasounds 13.19.4. Others 13.20. Japan Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 13.20.1. Uterine Fibroid Embolization 13.20.2. Magnetic Resonance Guided Focused Ultrasound 13.20.3. Myolysis 13.20.4. Endometrial Ablation 13.20.5. Hysterectomy 13.20.6. Myomectomy 13.21. Australia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 13.21.1. Subserosal Fibroids 13.21.2. Intramural Fibroids 13.21.3. Submucosal Fibroids 13.21.4. Others 13.22. Australia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 13.22.1. Medical Resonance Imaging (MRI) scanners 13.22.2. Computed Tomography (CT) 13.22.3. Ultrasounds 13.22.4. Others 13.23. Australia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 13.23.1. Uterine Fibroid Embolization 13.23.2. Magnetic Resonance Guided Focused Ultrasound 13.23.3. Myolysis 13.23.4. Endometrial Ablation 13.23.5. Hysterectomy 13.23.6. Myomectomy 13.24. Malaysia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 13.24.1. Subserosal Fibroids 13.24.2. Intramural Fibroids 13.24.3. Submucosal Fibroids 13.24.4. Others 13.25. Malaysia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 13.25.1. Medical Resonance Imaging (MRI) scanners 13.25.2. Computed Tomography (CT) 13.25.3. Ultrasounds 13.25.4. Others 13.26. Malaysia Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 13.26.1. Uterine Fibroid Embolization 13.26.2. Magnetic Resonance Guided Focused Ultrasound 13.26.3. Myolysis 13.26.4. Endometrial Ablation 13.26.5. Hysterectomy 13.26.6. Myomectomy 13.27. South Korea Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 13.27.1. Subserosal Fibroids 13.27.2. Intramural Fibroids 13.27.3. Submucosal Fibroids 13.27.4. Others 13.28. South Korea Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 13.28.1. Medical Resonance Imaging (MRI) scanners 13.28.2. Computed Tomography (CT) 13.28.3. Ultrasounds 13.28.4. Others 13.29. South Korea Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 13.29.1. Uterine Fibroid Embolization 13.29.2. Magnetic Resonance Guided Focused Ultrasound 13.29.3. Myolysis 13.29.4. Endometrial Ablation 13.29.5. Hysterectomy 13.29.6. Myomectomy 13.30. Thailand Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 13.30.1. Subserosal Fibroids 13.30.2. Intramural Fibroids 13.30.3. Submucosal Fibroids 13.30.4. Others 13.31. Thailand Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 13.31.1. Medical Resonance Imaging (MRI) scanners 13.31.2. Computed Tomography (CT) 13.31.3. Ultrasounds 13.31.4. Others 13.32. Thailand Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 13.32.1. Uterine Fibroid Embolization 13.32.2. Magnetic Resonance Guided Focused Ultrasound 13.32.3. Myolysis 13.32.4. Endometrial Ablation 13.32.5. Hysterectomy 13.32.6. Myomectomy 13.33. Vietnam Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 13.33.1. Subserosal Fibroids 13.33.2. Intramural Fibroids 13.33.3. Submucosal Fibroids 13.33.4. Others 13.34. Vietnam Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 13.34.1. Medical Resonance Imaging (MRI) scanners 13.34.2. Computed Tomography (CT) 13.34.3. Ultrasounds 13.34.4. Others 13.35. Vietnam Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 13.35.1. Uterine Fibroid Embolization 13.35.2. Magnetic Resonance Guided Focused Ultrasound 13.35.3. Myolysis 13.35.4. Endometrial Ablation 13.35.5. Hysterectomy 13.35.6. Myomectomy 13.36. Rest of Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 13.36.1. Subserosal Fibroids 13.36.2. Intramural Fibroids 13.36.3. Submucosal Fibroids 13.36.4. Others 13.37. Rest of Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 13.37.1. Medical Resonance Imaging (MRI) scanners 13.37.2. Computed Tomography (CT) 13.37.3. Ultrasounds 13.37.4. Others 13.38. Rest of Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 13.38.1. Uterine Fibroid Embolization 13.38.2. Magnetic Resonance Guided Focused Ultrasound 13.38.3. Myolysis 13.38.4. Endometrial Ablation 13.38.5. Hysterectomy 13.38.6. Myomectomy 13.39. Asia Pacific Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis 13.39.1. By Type 13.39.2. By Diagnosis 13.39.3. By Treatment 13.40. PEST Analysis 13.41. Key Trends 13.42. Key Development 14. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Overview 14.3. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type 14.4. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 14.4.1. Subserosal Fibroids 14.4.2. Intramural Fibroids 14.4.3. Submucosal Fibroids 14.4.4. Others 14.5. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis 14.6. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 14.6.1. Medical Resonance Imaging (MRI) scanners 14.6.2. Computed Tomography (CT) 14.6.3. Ultrasounds 14.6.4. Others 14.7. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Treatment 14.8. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 14.8.1. Uterine Fibroid Embolization 14.8.2. Magnetic Resonance Guided Focused Ultrasound 14.8.3. Myolysis 14.8.4. Endometrial Ablation 14.8.5. Hysterectomy 14.8.6. Myomectomy 14.9. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Country 14.10. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.10.5. Rest of Middle East & Africa 14.11. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Country 14.12. GCC Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 14.12.1. Subserosal Fibroids 14.12.2. Intramural Fibroids 14.12.3. Submucosal Fibroids 14.12.4. Others 14.13. GCC Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 14.13.1. Medical Resonance Imaging (MRI) scanners 14.13.2. Computed Tomography (CT) 14.13.3. Ultrasounds 14.13.4. Others 14.14. GCC Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 14.14.1. Uterine Fibroid Embolization 14.14.2. Magnetic Resonance Guided Focused Ultrasound 14.14.3. Myolysis 14.14.4. Endometrial Ablation 14.14.5. Hysterectomy 14.14.6. Myomectomy 14.15. South Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 14.15.1. Subserosal Fibroids 14.15.2. Intramural Fibroids 14.15.3. Submucosal Fibroids 14.15.4. Others 14.16. South Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 14.16.1. Medical Resonance Imaging (MRI) scanners 14.16.2. Computed Tomography (CT) 14.16.3. Ultrasounds 14.16.4. Others 14.17. South Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 14.17.1. Uterine Fibroid Embolization 14.17.2. Magnetic Resonance Guided Focused Ultrasound 14.17.3. Myolysis 14.17.4. Endometrial Ablation 14.17.5. Hysterectomy 14.17.6. Myomectomy 14.18. Nigeria Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 14.18.1. Subserosal Fibroids 14.18.2. Intramural Fibroids 14.18.3. Submucosal Fibroids 14.18.4. Others 14.19. Nigeria Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 14.19.1. Medical Resonance Imaging (MRI) scanners 14.19.2. Computed Tomography (CT) 14.19.3. Ultrasounds 14.19.4. Others 14.20. Nigeria Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 14.20.1. Uterine Fibroid Embolization 14.20.2. Magnetic Resonance Guided Focused Ultrasound 14.20.3. Myolysis 14.20.4. Endometrial Ablation 14.20.5. Hysterectomy 14.20.6. Myomectomy 14.21. Egypt Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 14.21.1. Subserosal Fibroids 14.21.2. Intramural Fibroids 14.21.3. Submucosal Fibroids 14.21.4. Others 14.22. Egypt Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 14.22.1. Medical Resonance Imaging (MRI) scanners 14.22.2. Computed Tomography (CT) 14.22.3. Ultrasounds 14.22.4. Others 14.23. Egypt Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 14.23.1. Uterine Fibroid Embolization 14.23.2. Magnetic Resonance Guided Focused Ultrasound 14.23.3. Myolysis 14.23.4. Endometrial Ablation 14.23.5. Hysterectomy 14.23.6. Myomectomy 14.24. Rest of Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 14.24.1. Subserosal Fibroids 14.24.2. Intramural Fibroids 14.24.3. Submucosal Fibroids 14.24.4. Others 14.25. Rest of Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 14.25.1. Medical Resonance Imaging (MRI) scanners 14.25.2. Computed Tomography (CT) 14.25.3. Ultrasounds 14.25.4. Others 14.26. Rest of Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 14.26.1. Uterine Fibroid Embolization 14.26.2. Magnetic Resonance Guided Focused Ultrasound 14.26.3. Myolysis 14.26.4. Endometrial Ablation 14.26.5. Hysterectomy 14.26.6. Myomectomy 14.27. Middle East & Africa Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis 14.27.1. By Type 14.27.2. By Diagnosis 14.27.3. By Treatment 14.28. PEST Analysis 14.29. Key Trends 14.30. Key Development 15. South America Uterine Fibroid Diagnostics and Therapeutics Market Analysis 15.1. Key Findings 15.2. South America Uterine Fibroid Diagnostics and Therapeutics Market Overview 15.3. South America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Type 15.4. South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 15.4.1. Subserosal Fibroids 15.4.2. Intramural Fibroids 15.4.3. Submucosal Fibroids 15.4.4. Others 15.5. South America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Diagnosis 15.6. South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 15.6.1. Medical Resonance Imaging (MRI) scanners 15.6.2. Computed Tomography (CT) 15.6.3. Ultrasounds 15.6.4. Others 15.7. South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 15.7.1. Uterine Fibroid Embolization 15.7.2. Magnetic Resonance Guided Focused Ultrasound 15.7.3. Myolysis 15.7.4. Endometrial Ablation 15.7.5. Hysterectomy 15.7.6. Myomectomy 15.8. South America Uterine Fibroid Diagnostics and Therapeutics Market Value Share Analysis, by Country 15.9. South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Country 15.9.1. Brazil 15.9.2. Mexico 15.9.3. Argentina 15.9.4. Rest of South America 15.10. South America Uterine Fibroid Diagnostics and Therapeutics Market Analysis, by Country 15.11. Brazil Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 15.11.1. Subserosal Fibroids 15.11.2. Intramural Fibroids 15.11.3. Submucosal Fibroids 15.11.4. Others 15.12. Brazil Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 15.12.1. Medical Resonance Imaging (MRI) scanners 15.12.2. Computed Tomography (CT) 15.12.3. Ultrasounds 15.12.4. Others 15.13. Brazil Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 15.13.1. Uterine Fibroid Embolization 15.13.2. Magnetic Resonance Guided Focused Ultrasound 15.13.3. Myolysis 15.13.4. Endometrial Ablation 15.13.5. Hysterectomy 15.13.6. Myomectomy 15.14. Mexico Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 15.14.1. Subserosal Fibroids 15.14.2. Intramural Fibroids 15.14.3. Submucosal Fibroids 15.14.4. Others 15.15. Mexico Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 15.15.1. Medical Resonance Imaging (MRI) scanners 15.15.2. Computed Tomography (CT) 15.15.3. Ultrasounds 15.15.4. Others 15.16. Mexico Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 15.16.1. Uterine Fibroid Embolization 15.16.2. Magnetic Resonance Guided Focused Ultrasound 15.16.3. Myolysis 15.16.4. Endometrial Ablation 15.16.5. Hysterectomy 15.16.6. Myomectomy 15.17. Argentina Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 15.17.1. Subserosal Fibroids 15.17.2. Intramural Fibroids 15.17.3. Submucosal Fibroids 15.17.4. Other 15.18. Argentina Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 15.18.1. Medical Resonance Imaging (MRI) scanners 15.18.2. Computed Tomography (CT) 15.18.3. Ultrasounds 15.18.4. Others 15.19. Argentina Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 15.19.1. Uterine Fibroid Embolization 15.19.2. Magnetic Resonance Guided Focused Ultrasound 15.19.3. Myolysis 15.19.4. Endometrial Ablation 15.19.5. Hysterectomy 15.19.6. Myomectomy 15.20. Rest of South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Type 15.20.1. Subserosal Fibroids 15.20.2. Intramural Fibroids 15.20.3. Submucosal Fibroids 15.20.4. Others 15.21. Rest of South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Diagnosis 15.21.1. Medical Resonance Imaging (MRI) scanners 15.21.2. Computed Tomography (CT) 15.21.3. Ultrasounds 15.21.4. Others 15.22. Rest of South America Uterine Fibroid Diagnostics and Therapeutics Market Forecast, by Treatment 15.22.1. Uterine Fibroid Embolization 15.22.2. Magnetic Resonance Guided Focused Ultrasound 15.22.3. Myolysis 15.22.4. Endometrial Ablation 15.22.5. Hysterectomy 15.22.6. Myomectomy 15.23. South America Uterine Fibroid Diagnostics and Therapeutics Market Attractiveness Analysis 15.23.1. By Type 15.23.2. By Diagnosis 15.23.3. By Treatment 15.24. PEST Analysis 15.25. Key Trends 15.26. Key Development 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Treatments and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Treatments 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Roche Ltd 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Abbott Laboratories 16.3.3. Becton 16.3.4. Dickinson and Company and Siemens Healthcare 16.3.5. AstraZeneca 16.3.6. Cook Medical Inc. 16.3.7. Boston Scientific Corporation 16.3.8. GE Healthcare 16.3.9. AbbVie Inc. 16.3.10. Hologic

About This Report

Report ID 72483
Category Healthcare
Published Date September 2020
No of Pages 223
Contact Us